ISSN: 1300-7777 E-ISSN: 1308-5263
Acquired Hemophilia in Pediatric Population [Turk J Hematol]
Turk J Hematol. 2002; 19(2): 199-202

Acquired Hemophilia in Pediatric Population

Kaan Kavaklı1, Güngör Nişli1, Yeşim Aydınok1, Nazan Çetingül1, Deniz Yılmaz1, Tülay Kavaklı2
1Department Of Pediatric Hematology And Oncology, Ege University Hospital, İzmir, Turkey
2Department Of Pediatrics, Dr. Behcet Uz’s Children Hospital, İzmir, Turkey

The development of acquired inhibitors against the factor VIII protein in childhood period, is a very rare disorder in nonhemophiliac persons but may be clinically important condition due to potential serious bleedings. We have investigated acquired hemophilia development frequency in children with potential high risk groups. Totally 483 nonhemophiliac children including healthy controls were enrolled the study. Age range was 2 to 20 years and mean age was 11 ± 5.4 years. Risk groups for acquired hemophilia were selected among sick children with transfusion dependent ß- thalassemia major (n= 75), children with malignancy (n= 55), asthma bronchiale (n= 65), type I insulin dependent diabetes mellitus (n= 63), collagen tissue disorders (n= 35). Age-matched 190 healthy children were selected as for healthy control group. Inhibitor tests were performed by the method of Bethesda assay. We have found only two patients who had acquired factor VIII inhibitor among 483 children. These two patients were solid tumor (osteosarcoma) and type I insulin dependent diabetes mellitus. Other risk groups and healthy controls have not inhibitor positivity. As a conclusion, acquired inhibitors should be considered for the differential diagnosis of unusual bleeding episodes in patients who had risk factors of all age groups including childhood period.

Keywords: Inhibitor, Hemophilia, Acquired hemophilia, Antifactor VIII antibody.


Kaan Kavaklı, Güngör Nişli, Yeşim Aydınok, Nazan Çetingül, Deniz Yılmaz, Tülay Kavaklı. Acquired Hemophilia in Pediatric Population. Turk J Hematol. 2002; 19(2): 199-202

Corresponding Author: Kaan Kavaklı, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2017) = 0.650